Medication safety in chronic kidney disease DOI
Sonal Singh

Current Opinion in Nephrology & Hypertension, Journal Year: 2023, Volume and Issue: 32(5), P. 434 - 438

Published: June 8, 2023

Purpose of review Several drugs cause nephrotoxicity and accelerate progression chronic kidney disease (CKD). The objective this is to summarize recent evidence on that either increase the risk nephrotoxicity, CKD or drug induced harm in patients with CKD. Recent findings Bisphosphonates hypnotics CKD, whereas denosumab does not Tenofovir disoproxil fumarate (TDF) increases renal tubular toxicity adverse effects bone, but alafenamide (TAF) amibufenamide (TMF) have favorable safety profile kidneys bones. Although no dosage adjustment needed for Oral Nirmatrelvir/Ritonavir mild impairment coronavirus 2019, reduced twice daily those moderate impairment. It recommended severe prescribing information recommend use remdesevir below glomerular filtration rate (eGFR) < 30 ml/min studies suggest may be safe effective varying levels severity. Molnupiravir require dose Summary medications development acute injury Close attention select appropriate safer alternatives reduce drug-induced

Language: Английский

Acute kidney injury with COVID-19: Mechanisms, management, and long-term outcomes DOI
Monica Cortinovis, Norberto Perico, Luca Perico

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 507 - 532

Published: Jan. 1, 2025

Language: Английский

Citations

0
Safety of Edaravone in real-world use: analysis based on FDA adverse event reporting system DOI
Tao Peng, Nan Hu, Lan Huang

et al.

Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

Edaravone is a novel free radical scavenger utilized to treat amyotrophic lateral sclerosis (ALS). However, long-term safety data remain limited. Adverse event reports related edaravone from the second quarter of 2017 2024 were extracted US Food and Drug Administration (FDA) Event Reporting System database (FAERS). Disproportionality analysis was conducted utilizing reporting odds ratio (ROR), proportional (PRR), Bayesian confidence propagation neural network (BCPNN), multi-item gamma Poisson shrinker (MGPS) algorithms. A total 3,149 adverse analyzed. The most common reactions included systemic disorders administration site reactions, nervous system disorders, respiratory surgical medical procedures. New reaction signals disseminated intravascular coagulation, gastric fistula, sputum retention, excessive salivation, fractures, elevated cystatin C. median onset time for events 43 days (interquartile range: 7-173 days). This study confirmed previously reported identified several new ones associated with edaravone. These findings provide valuable insights optimizing ALS patient management highlight need further research into mechanisms these reactions.

Language: Английский

Citations

0
Drug-associated hyperprolactinemia: a comprehensive disproportionality analysis based on the FAERS database DOI

Jinhua Liu,

Li‐Ping Xue, Xinyu Fang

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177551 - 177551

Published: March 1, 2025

Language: Английский

Citations

0
Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database DOI
Lihua Tong,

Yanling Yuan,

Wanming He

et al.

Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

The precise incidence of immune-related adverse events (irAEs) remains unclear. This pharmacovigilance study investigated acute pancreatitis (AP) associated with immune checkpoint inhibitors (ICIs) using real-world data from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis employing reporting odds ratios (RORs) was conducted to detect AP signals in ICI-treated patients compared entire FAERS database. A total 152,042 individual were included dataset which we identified a cohort 921 (AEs). severe outcome death, rate 13.6% (125/921).Immune inhibitor (ICI)-related AEs classified into two categories (pancreatitis and immune-mediated pancreatitis) based on type event observed. ICI treatments significantly correlated risk ICIs-induced pancreatitis(AP) but varied among different drugs. median time onset 57 days, occurring throughout first year post-ICI initiation. Our findings provide an enhanced understanding potential related actionable insights for early detection management pancreatic events.

Language: Английский

Citations

0
Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials DOI Creative Commons

Golnaz Shams,

Asma Kazemi,

Khatereh Jafaryan

et al.

Clinics, Journal Year: 2023, Volume and Issue: 78, P. 100200 - 100200

Published: Jan. 1, 2023

Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about detrimental remdesivir kidney function which might consequently lead to Acute Kidney Injury (AKI). In this study, we aim determine whether use in COVID-19 patients increases risk AKI.

Language: Английский

Citations

9
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials DOI
Wei Chen,

Jiyi Xie,

Chen Gao

et al.

Gynecologic Oncology, Journal Year: 2024, Volume and Issue: 182, P. 108 - 114

Published: Jan. 31, 2024

Language: Английский

Citations

3
Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center DOI Creative Commons

Hsuan-Yu Chang,

Chia‐Chen Hsu,

Li-Fang Hu

et al.

Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)

Published: June 3, 2024

Background Literature on the safety of remdesivir in hospitalized COVID-19 patients with severe renal impairment is limited. We aimed to investigate and effectiveness this population.

Language: Английский

Citations

3
Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System DOI Open Access
Xiaotong Li, Liyuan Zhou, Martina Gaggl

et al.

International Journal of Clinical Pharmacy, Journal Year: 2023, Volume and Issue: 45(2), P. 509 - 514

Published: March 24, 2023

Language: Английский

Citations

7
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system DOI Creative Commons

Yankun Liang,

Lin Ma, Yuting Wang

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 31, 2023

Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as basis for our study, which relies on Food and Drug Administration Adverse Event Reporting System (FAERS). The objective is to extract adverse event (AE) signals associated with molnupiravir from FAERS database, thereby providing a reference post-marketing monitoring of events. Specifically, we extracted individual case safety reports (ICSRs) focusing cases COVID-19 indications identified primary suspect drug. Descriptive analysis data was performed, followed by four disproportionality analyses using reporting odds ratio (ROR) method. These were conducted across levels, encompassing overall data, health professionals, well age gender differentiations, ensuring robustness results. In total, 116,576 ICSRs 2,285 extracted. Notably, after excluding unknown or gender, higher proportion molnupiravir-related observed among individuals aged 65 years older (70.07%) women (54.06%). most frequently reported events AE gastrointestinal disorders, skin subcutaneous tissue disorders. Moreover, exhibited risk cardiac hepatobiliary renal urinary vascular conclusion, this study found demonstrated lower serious compared other RNA antiviral drugs like remdesivir in patients under old. However, close its still necessary elderly above. Further studies are warranted continuously assess profile usage increases, especially high populations.

Language: Английский

Citations

7
A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system DOI Creative Commons
Jingyi Zhang, Yuting Guo,

Chunyan Wei

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: June 21, 2024

Statins were regarded as a main medication for managing hypercholesterolemia. Administration of statin therapy could reduce the incidence cardiovascular disease in individuals diagnosed with type 2 diabetes mellitus (DM), which was recognized by multipal clinical guidelines. But previous studies had conflicting results on whether long-term use statins benefit renal function diabetic patients.

Language: Английский

Citations

2